WO2006026604A2 - Methods for promoting wound healing - Google Patents

Methods for promoting wound healing Download PDF

Info

Publication number
WO2006026604A2
WO2006026604A2 PCT/US2005/030798 US2005030798W WO2006026604A2 WO 2006026604 A2 WO2006026604 A2 WO 2006026604A2 US 2005030798 W US2005030798 W US 2005030798W WO 2006026604 A2 WO2006026604 A2 WO 2006026604A2
Authority
WO
WIPO (PCT)
Prior art keywords
product
growth factor
wound healing
wound
patient
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2005/030798
Other languages
English (en)
French (fr)
Other versions
WO2006026604A3 (en
Inventor
Eli Wilner
Mathew Cohen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
POSNER SARI
Advanced Viral Research Corp
Original Assignee
POSNER SARI
Advanced Viral Research Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by POSNER SARI, Advanced Viral Research Corp filed Critical POSNER SARI
Priority to AU2005279921A priority Critical patent/AU2005279921A1/en
Priority to EP05795551A priority patent/EP1804817A4/en
Priority to JP2007530256A priority patent/JP2008511652A/ja
Priority to CA002578212A priority patent/CA2578212A1/en
Publication of WO2006026604A2 publication Critical patent/WO2006026604A2/en
Publication of WO2006026604A3 publication Critical patent/WO2006026604A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/01—Hydrolysed proteins; Derivatives thereof
    • A61K38/012—Hydrolysed proteins; Derivatives thereof from animals
    • A61K38/018—Hydrolysed proteins; Derivatives thereof from animals from milk
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/01—Hydrolysed proteins; Derivatives thereof
    • A61K38/012—Hydrolysed proteins; Derivatives thereof from animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution

Definitions

  • Bacterial wound infection is the most common local cause for prolonged wound healing. Human skin is typically colonized by a number of microorganisms, including Candida albicans, Staphylococcus epidermidis, Staphylococcus aureus, and some Streptococcus strains. Thus, any wound which exposes underlying tissues to the environment becomes infected with at least resident microbial flora. Wounds which are well tended and in highly vascularized tissue resist infection, while those in ischemic tissue are much more susceptible to infection.
  • in combination refers to the use of more than one prophylactic and/or therapeutic agents.
  • the use of the term “in combination” does not restrict the order in which prophylactic and/or therapeutic agents are administered to a subject with a disorder.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Nutrition Science (AREA)
  • Dermatology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Surgery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
PCT/US2005/030798 2004-08-27 2005-08-29 Methods for promoting wound healing Ceased WO2006026604A2 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
AU2005279921A AU2005279921A1 (en) 2004-08-27 2005-08-29 Methods for promoting wound healing
EP05795551A EP1804817A4 (en) 2004-08-27 2005-08-29 METHODS OF PROMOTING WOUND HEALING
JP2007530256A JP2008511652A (ja) 2004-08-27 2005-08-29 創傷治癒の促進方法
CA002578212A CA2578212A1 (en) 2004-08-27 2005-08-29 Methods for promoting wound healing

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US60532004P 2004-08-27 2004-08-27
US60/605,320 2004-08-27

Publications (2)

Publication Number Publication Date
WO2006026604A2 true WO2006026604A2 (en) 2006-03-09
WO2006026604A3 WO2006026604A3 (en) 2006-12-07

Family

ID=36000687

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2005/030798 Ceased WO2006026604A2 (en) 2004-08-27 2005-08-29 Methods for promoting wound healing

Country Status (5)

Country Link
EP (1) EP1804817A4 (enExample)
JP (1) JP2008511652A (enExample)
AU (1) AU2005279921A1 (enExample)
CA (1) CA2578212A1 (enExample)
WO (1) WO2006026604A2 (enExample)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8084239B2 (en) 1996-10-22 2011-12-27 Ohr Pharmaceuticals, Inc Preparation of a therapeutic composition
CN108339112A (zh) * 2016-12-30 2018-07-31 亚宝药业集团股份有限公司 一种用于促进创伤愈合、褥疮修复、术后应激性溃疡愈合的营养组合物
US10183921B2 (en) 2013-04-18 2019-01-22 Qbiotics Limited Methods and compositions for wound healing

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA019332B1 (ru) * 2009-09-29 2014-02-28 Юнайтед Текнолоджис Ут Аг Состав для ухода за полостью рта, содержащий человеческий рекомбинантный интерлейкин-1
WO2025049974A1 (en) * 2023-09-01 2025-03-06 Eom Pharmaceuticals Inc. Methods of treating inflammatory bowel diseases
CN118121594B (zh) * 2024-05-06 2024-07-02 广州市朝利良生物科技有限公司 Eh-p006n在制备促进伤口愈合药物中的应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5849196A (en) * 1996-10-07 1998-12-15 Immune Modulation Maximum Composition containing peptides and nucleic acids and methods of making same
US6528098B2 (en) * 1996-10-22 2003-03-04 Advanced Viral Research Corp. Preparation of a therapeutic composition
US6303153B1 (en) * 1996-10-22 2001-10-16 Advanced Viral Research Corp. Preparation of a therapeutic composition
US5807839A (en) * 1997-04-15 1998-09-15 Advanced Viral Research Corp. Method for stimulating red blood cell production
CA2285572A1 (en) * 1997-04-15 1998-10-22 Advanced Viral Research Corp. A method for treating papillomavirus infections
US7439234B2 (en) * 1997-04-15 2008-10-21 Advanced Viral Research Corporation Method for treating cancer patients undergoing chemotherapy
WO1998046240A1 (en) * 1997-04-15 1998-10-22 Advanced Viral Research Corp. Topical treatment of skin diseases and eye afflictions
US5902786A (en) * 1997-04-15 1999-05-11 Advanced Viral Research Corp. Treatment of basal cell carcinoma with product R, a peptide-nucleic acid preparation
US20020107184A1 (en) * 1997-11-04 2002-08-08 Shalom Z. Hirschman Method for treating melanoma

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of EP1804817A4 *

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8084239B2 (en) 1996-10-22 2011-12-27 Ohr Pharmaceuticals, Inc Preparation of a therapeutic composition
US10183921B2 (en) 2013-04-18 2019-01-22 Qbiotics Limited Methods and compositions for wound healing
US10183922B2 (en) 2013-04-18 2019-01-22 Qbiotics Limited Methods and compositions for wound healing
US10822317B2 (en) 2013-04-18 2020-11-03 QBiotics Pty Ltd Methods and compositions for wound healing
CN108339112A (zh) * 2016-12-30 2018-07-31 亚宝药业集团股份有限公司 一种用于促进创伤愈合、褥疮修复、术后应激性溃疡愈合的营养组合物
CN108339112B (zh) * 2016-12-30 2023-04-21 亚宝药业集团股份有限公司 一种用于促进创伤愈合、褥疮修复、术后应激性溃疡愈合的营养组合物

Also Published As

Publication number Publication date
WO2006026604A3 (en) 2006-12-07
EP1804817A4 (en) 2009-11-11
JP2008511652A (ja) 2008-04-17
EP1804817A2 (en) 2007-07-11
AU2005279921A1 (en) 2006-03-09
CA2578212A1 (en) 2006-03-09

Similar Documents

Publication Publication Date Title
RU2712635C1 (ru) Композиции для содействия заживлению кожных язв и ран
US9233126B2 (en) Platelet-rich plasma compositions
AU1462392A (en) Use of gm-csf and g-csf to promote accelerated wound healing
US7858582B2 (en) Ophthalmic hGM-CSF preparation
US7645733B2 (en) Tissue protective cytokines for the treatment and prevention of sepsis and the formation of adhesions
RU2148988C1 (ru) Усовершенствованная лекарственная форма человеческого интерферона-свеча
WO2006026604A2 (en) Methods for promoting wound healing
BG62239B1 (bg) Приложение на лизозимен димер
RU2115428C1 (ru) Способ лечения иммуносупрессии при сепсисе у человека
CN112933214A (zh) 一种促进伤口愈合的组合物
RU2209074C2 (ru) Состав для лечения ожогов
RU2228763C1 (ru) Способ лечения гнойных ран
Gültekin et al. Treatment of a Full-Thickness Skin Wound in Gluteal Region of the Vervet Monkey with Topical Insulin
RU2152214C1 (ru) Способ лечения острого остеомиелита
TW202202145A (zh) 促進傷口癒合的有機鍺藥物及其使用方法
US6123937A (en) Applications of lysozyme dimer
RU2202356C2 (ru) Способ стимуляции репаративных процессов длительно незаживающих ран и трофических язв
US20070025963A1 (en) Methods for reduction of scar tissue formation
EP2089050A2 (en) Il- 17b for use in wound healing
EA002267B1 (ru) Ранозаживляющий, противовоспалительный и противоинфекционный лекарственный препарат
RU2003344C1 (ru) Способ лечени ожоговой болезни
CN116585457A (zh) 一种用于治疗难愈性创面的组合物及其制剂与应用
CN119798373A (zh) 一种促进伤口愈合的药物组合物及其制备方法
US20190321412A1 (en) Methods and compositions using dehydrated human amnion/chorion membrane allograft and amnionic membrane allograft suspensions for the treatment of hair loss
MXPA03006346A (es) Composiciones de cianoacrilato para el tratamiento profilactico o terapeutico de enfermedades que se manifiestan por si mismas en el tejido cutaneo y/o danan al mismo.

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU LV MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2007530256

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 2578212

Country of ref document: CA

NENP Non-entry into the national phase in:

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2005279921

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2005795551

Country of ref document: EP

ENP Entry into the national phase in:

Ref document number: 2005279921

Country of ref document: AU

Date of ref document: 20050829

Kind code of ref document: A

WWP Wipo information: published in national office

Ref document number: 2005279921

Country of ref document: AU

WWP Wipo information: published in national office

Ref document number: 2005795551

Country of ref document: EP